Atlanta, Georgia (PRWEB) October 22, 2013
Jeevan BioSciences, Inc. (http://www.jeevanbiosciences.com) a start-up biotechnology company co-founded by Dr. Rodney Nash, PhD, a former Neuroscience Post-Doctoral Fellow at Emory University, today announces the commercial release of its first product Neuro – XTM Tissue Culture Media; the first 100% serum-free and xeno-free media product available on the market. Neuro-XTM is a proprietary patent pending chemically defined media specifically formulated for use in the growth of human cells and tissue without the need for serum or other animal products. The product was originally developed to support the growth of neuronal cells, but has been engineered to support the growth of multiple types of human cells including U87, HeLa, Neural progenitors, MCF7, Raji, A549, 143B, HS587T, PSCs, Cancer Stem Cells, Foreskin Fibroblasts, as well as MEF and 3T3 mouse cells. Researchers using Neuro-XTM are discovering that the product supports additional cell types on an almost weekly basis.
“It is well-known that serum is essentially a contaminant that significantly affects the ability to obtain reliable and reproducible results when it comes to cell culturing, and we knew that developing a serum-free and xeno-free media would solve this problem”, says Dr. Rodney Nash, CEO of Jeevan BioScience.
Neuro-XTM is a proprietary DMEM/F-12 base media that contains no animal-derived components or albumin, and efficiently grows all types of human cells and tissue including cancer cells, stem cells, neuronal cells, foreskin fibroblast, and muscle cells. The media also effectively grows mouse cells and other tissue as well. “We are excited about the possibilities when you consider the number of different cell types that Neuro-XTM supports”, continues Dr. Nash. “We constantly hear about additional cell types that the media supports from other researchers around the country that are using the media, and we encourage them to run new experiments and expand the possibilities of their research”.
“This media maintains stemness in neuronal progenitor cells,” says Dr. Jie Xu, Ph.D. a researcher at Georgia State University. “We have been able to successfully infect these cells with Sindbis virus and maintain neuronal progenitor cells using Neuro-XTM media, and now we intend to include this media as an important tool in our research initiatives”. Neuro-XTM media is also being used by cancer researchers across the country. “We are very impressed with Neuro-XTM in maintaining and differentiating patient glioma tumor-derived (primary cells) cancer stem cell,” says Carol Tucker-Burden a researcher at Emory University. “The Neuro-XTM media maintains the tumor-derived neurospheres similarly in comparison to our supplemented media without the need for us to be concerned with serum, which we consider to be a contaminant”.
Neuro-XTM is available at an introductory price of US$199.00 per 500ML bottle, and is distributed by World Wide Medical Products, Inc. (http://www.wwmponline.com), a laboratory products and services company located in Bristol Pennsylvania. “We are very impressed with the Neuro-XTM product and the team at Jeevan Biosciences”, says David Spaventa, Director of Sales & Strategic Alliances at World Wide Medical Products. “Prior to our relationship with Jeevan we had never distributed a media product, but decided to distribute Neuro-XTM given its unique quality as the only true serum-free and xeno-free media available on the market, and the significant growth potential for a product like this”. Free samples of Neuro-XTM media are available in units of 50mL and 100mL from World Wide Medical Products (1-866-889-9967).
Additional information about the Neuro-XTM product can be found on the Jeevan Biosciences website (http://www.jeevanbiosciences.com,) including product brochures and scientific papers that provide technical details about how the media is being used in scientific research and drug development.
About Jeevan Bio Sciences, Inc.
Jeevan Biosciences, Inc. is an Atlanta-based biotechnology company committed to the development of cellular models for cancer and neurologic disease research and drug testing. Through accurate cellular model systems, we strive to bridge the gap between research and medicine to improve the quality of life for patient populations who would benefit the most.